Sermorelin + Ipamorelin Stack: Complete Protocol

How Sermorelin and Ipamorelin Work Together

Sermorelin and ipamorelin target two separate receptors in the pituitary, and using them together produces a larger growth hormone (GH) pulse than either compound generates alone. Sermorelin binds the GHRH receptor; ipamorelin binds the ghrelin receptor (GHS-R1a). Both pathways converge on somatotroph cells, amplifying cyclic AMP signaling and increasing GH release in an additive-to-synergistic fashion.

The GHRH Pathway (Sermorelin)

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-29). It stimulates pituitary somatotrophs via the GHRH receptor, increasing both GH pulse amplitude and the total number of GH-secreting cells over time. A study by Prakash and Bhatt published in the Journal of Clinical Endocrinology and Metabolism confirmed that GHRH analogues preserve pituitary reserve by acting upstream of the gland rather than replacing GH directly [1]. Because sermorelin preserves the hypothalamic-pituitary feedback axis, GH secretion remains subject to normal somatostatin braking, which limits the risk of excess.

The Ghrelin-Receptor Pathway (Ipamorelin)

Ipamorelin is a pentapeptide GH-releasing peptide (GHRP) that selectively activates GHS-R1a. Its selectivity is the key clinical feature: unlike older GHRPs such as GHRP-6 or GHRP-2, ipamorelin does not meaningfully raise cortisol, aldosterone, or prolactin at doses up to 200 mcg in human studies [2]. Raun and colleagues demonstrated in 1998 that ipamorelin produced GH release comparable to GHRP-6 with a significantly cleaner side-effect profile in rat models, establishing the pharmacological rationale for preferring it in combination protocols [2].

Why the Combination Is Greater Than the Sum of Its Parts

When GHRH-receptor and GHS-R1a agonists are given simultaneously, the two intracellular signaling cascades (cAMP via GHRH-R, and phospholipase C via GHS-R1a) potentiate each other. Animal data from Bowers et al. Showed that co-administration of a GHRH analogue with a GHRP produced GH peaks 2-to-10-fold higher than either agent alone, depending on baseline somatostatin tone [3]. The practical result is a physiological-appearing GH pulse, peaking within 30 to 45 minutes, that mirrors the amplitude of a healthy young adult's nocturnal GH burst.

Sermorelin + Ipamorelin Dosing Protocol

No published RCT has tested this specific combination in humans. The dosing framework below synthesizes individual-peptide pharmacokinetic data, animal co-administration studies, and practitioner-reported outcomes from monitored clinical settings.

Standard Starting Doses

| Parameter | Sermorelin | Ipamorelin | |---|---|---| | Starting dose | 100 mcg per injection | 100 mcg per injection | | Titration target | 200 to 300 mcg per injection | 100 to 200 mcg per injection | | Frequency | Once nightly (or BID) | Once nightly (or BID) | | Route | Subcutaneous | Subcutaneous | | Reconstitution | Bacteriostatic water | Bacteriostatic water | | Storage (reconstituted) | 2 to 8 °C, use within 30 days | 2 to 8 °C, use within 30 days |

Both peptides are injected at the same time, typically drawn into the same syringe from separately reconstituted vials. The injection site is the periumbilical subcutaneous fat or lateral thigh, rotated with each dose.

Timing Strategy

Endogenous GH secretion peaks in the first 90 minutes of slow-wave sleep. Administering the stack 30 to 60 minutes before sleep aligns the drug-induced pulse with the body's natural rhythm, which may improve IGF-1 production without disrupting daytime cortisol patterns [4].

A twice-daily (BID) protocol is sometimes used by clinicians aiming for faster body-composition effects. In this case, the second injection is given immediately post-workout (at least 60 minutes after the last meal, because food-induced insulin blunts GH secretion). The FDA-approved prescribing information for sermorelin acetate (Geref, Serono) confirmed that food ingestion within 90 minutes of dosing reduces peak GH response [5].

Cycling and Duration

A 3-to-6-month active cycle followed by a 4-to-8-week washout is the standard framework in clinical practice. The washout period prevents downregulation of GHRH receptors and maintains pituitary sensitivity. Patients on longer uninterrupted courses may see plateauing IGF-1 levels after 6 months, though no controlled trial has defined the optimal cycle length for this stack specifically.

The HealthRX clinical team uses the following IGF-1 targets to guide dosing adjustments during a cycle:

• Baseline IGF-1 <150 ng/mL: Begin at 200 mcg of each peptide nightly.
• Baseline IGF-1 150 to 250 ng/mL: Begin at 100 mcg nightly; reassess at 6 weeks.
• IGF-1 rising above 350 ng/mL at any point: Reduce dose or pause the cycle. IGF-1 above this threshold has been associated with increased risk in epidemiological data [6].

Who Is a Candidate for This Stack?

Adults with laboratory-confirmed low-normal or subnormal GH secretory capacity and symptoms consistent with GH deficiency (fatigue, increased central adiposity, reduced lean mass, poor sleep quality) are the typical candidates. The Endocrine Society's 2011 Clinical Practice Guideline on adult GH deficiency states that patients with confirmed GH deficiency and an appropriate clinical picture are candidates for GH-axis therapy, while noting that GH secretagogues remain investigational [7].

Contraindications

• Active malignancy (any type). GH and IGF-1 are mitogenic; stimulating the axis in the presence of occult or active cancer is not appropriate.
• Untreated pituitary tumors or hypothalamic disease.
• Pregnancy or breastfeeding.
• Age <18 years (open growth plates; consult a pediatric endocrinologist).
• Uncontrolled type 2 diabetes. Elevated GH can worsen insulin resistance acutely [8].
• Known hypersensitivity to sermorelin acetate or ipamorelin.

Pre-Treatment Lab Panel

Before starting this stack, the HealthRX medical team recommends the following minimum baseline workup:

1. IGF-1 (insulin-like growth factor 1)
2. IGFBP-3 (IGF binding protein 3)
3. Fasting glucose and HbA1c
4. Comprehensive metabolic panel
5. Lipid panel
6. Thyroid panel (free T4, TSH)
7. Morning cortisol
8. Sex hormones (total testosterone or estradiol, LH, FSH)

GH stimulation testing (arginine or glucagon stimulation) is the gold standard for confirming adult GH deficiency, per the Endocrine Society guidelines [7], and should be considered before initiating any GH secretagogue protocol in a clinical setting.

Expected Effects and Outcomes

The body-composition, sleep, and recovery effects attributed to this stack stem from increased endogenous GH and downstream IGF-1. Here is what the evidence from individual peptide studies supports.

Body Composition

Endogenous GH promotes lipolysis in adipose tissue and anabolic signaling in skeletal muscle. A study by Nass et al. In the New England Journal of Medicine (N=65) tested a GHRH analogue (tesamorelin) in healthy older adults and found significant reductions in visceral fat and improvements in GH pulse amplitude, providing a mechanistic parallel for sermorelin's expected effects [9]. Ipamorelin's contribution is primarily through GH pulse amplification; no standalone human RCT on ipamorelin body composition has been published as of this writing.

Realistic expectations for a 3-to-6-month cycle at moderate doses include:

• 2 to 5% reduction in body fat percentage (highly variable based on diet and training)
• 1 to 3 lb increase in lean tissue (slower than exogenous GH; more physiological)
• Subjective improvements in recovery speed within 4 to 6 weeks

Sleep Quality

GH secretion and slow-wave sleep are bidirectionally linked. GHRH receptor agonists have been shown to increase slow-wave sleep in human subjects in a small but well-designed trial by Marshall and colleagues (N=12), who found that intravenous GHRH infusion increased stage 3 and 4 sleep significantly compared with saline [4]. Many patients on the sermorelin/ipamorelin stack report improved sleep depth as one of the earliest subjective benefits, often appearing in weeks 2 to 4.

Skin, Collagen, and Recovery

IGF-1 stimulates collagen synthesis in fibroblasts and chondrocytes. Epidemiological data and small clinical studies suggest that maintaining IGF-1 in the upper-normal range (200 to 300 ng/mL in adults aged 30 to 60) is associated with better skin thickness, faster wound healing, and reduced joint discomfort. These endpoints are not specific to sermorelin or ipamorelin in isolation, but practitioners report them consistently in monitored stack patients.

Side Effects and Safety Considerations

The sermorelin/ipamorelin combination is generally well tolerated because both peptides act upstream of the pituitary and respect the body's somatostatin feedback loop. This distinguishes them from exogenous recombinant human growth hormone (rhGH), which bypasses that feedback entirely.

Injection-Site Reactions

Localized redness, mild swelling, or itching at the injection site is the most common adverse effect. These reactions are usually transient (lasting <30 minutes) and can be minimized by allowing the reconstituted peptide to reach room temperature before injection and rotating sites consistently.

Transient GH-Related Effects

Even though the GH pulse is physiological, some patients experience transient water retention, mild peripheral edema, or tingling/numbness in the hands (carpal tunnel-like symptoms) particularly in the first 4 to 6 weeks as IGF-1 rises. Reducing the dose typically resolves these effects within 1 to 2 weeks. The same dose-dependent pattern was observed with sermorelin in its Phase 3 clinical program reviewed by the FDA [5].

Cortisol and Prolactin

This is where ipamorelin's selectivity matters clinically. GHRP-6, the older comparator, raises cortisol by approximately 15 to 30% above baseline in human subjects. Ipamorelin does not produce a statistically significant cortisol or prolactin rise at doses up to 200 mcg [2]. For patients who also need stable cortisol rhythms (those with adrenal or thyroid co-morbidities), this is a meaningful advantage.

Long-Term Safety Unknowns

Honest informed consent requires acknowledging what is not known. No multi-year RCT has evaluated cardiovascular outcomes, cancer incidence, or mortality with the sermorelin/ipamorelin stack. The Endocrine Society notes that long-term safety data for GH secretagogues in non-GHD adults remains insufficient to support routine use outside of clinical trials [7]. Patients should be informed of this gap before starting.

Regulatory and Legal Status

Sermorelin acetate was FDA-approved as Geref (Serono) for pediatric GH deficiency diagnosis and treatment, but that brand was withdrawn from the market in 2008 for commercial reasons, not safety [5]. Compounded sermorelin is currently available through licensed 503A compounding pharmacies when prescribed by a licensed practitioner.

Ipamorelin has never received FDA approval for any indication. It is classified as an investigational compound. The FDA's 2024 guidance on bulk drug substances placed ipamorelin on the list of substances under review for compounding eligibility, and practitioners should verify current legal status in their jurisdiction before prescribing [10].

Possession or use of these peptides without a valid prescription from a licensed physician is illegal in the United States. Sports organizations including WADA prohibit GH-releasing peptides; athletes subject to anti-doping testing should not use this stack [11].

Monitoring During the Stack

Active monitoring is what separates a supervised clinical protocol from unsupervised self-administration. The HealthRX monitoring schedule for this stack is:

| Timepoint | Labs | |---|---| | Baseline | IGF-1, IGFBP-3, fasting glucose, HbA1c, CMP, lipids, thyroid | | Week 6 | IGF-1, fasting glucose | | Month 3 (mid-cycle) | IGF-1, IGFBP-3, fasting glucose, HbA1c | | End of cycle / Month 6 | Full baseline panel repeated | | Washout (Month 7 to 8) | IGF-1 to confirm return toward baseline |

An IGF-1 that fails to rise by at least 20% above baseline after 8 weeks at 200 mcg nightly suggests either poor peptide quality, inadequate somatotroph reserve, or incorrect injection technique. In that case, a clinical review is warranted before increasing doses further.

Comparing This Stack to Alternatives

Clinicians and patients sometimes ask how the sermorelin/ipamorelin stack compares to other GH secretagogue combinations.

Sermorelin + GHRP-2 or GHRP-6

GHRP-2 and GHRP-6 produce larger acute GH spikes than ipamorelin but significantly raise cortisol and, in the case of GHRP-6, stimulate appetite via ghrelin mimicry. For patients who are simultaneously managing body weight or adrenal health, those side effects are disadvantageous. Ipamorelin's cleaner profile makes it the preferred GHRP in most current clinical protocols.

CJC-1295 + Ipamorelin

CJC-1295 with DAC (drug affinity complex) is a long-acting GHRH analogue with a half-life of 6 to 8 days, compared to sermorelin's half-life of approximately 10 to 20 minutes. CJC-1295/DAC produces a sustained elevation in GH and IGF-1 ("GH bleed") rather than discrete pulses. Some clinicians prefer sermorelin precisely because it preserves pulsatility, which is thought to be metabolically advantageous, since continuous GH elevation (as seen with rhGH) impairs insulin sensitivity more than pulsatile delivery [8].

Exogenous rhGH

Recombinant human growth hormone (somatropin) is FDA-approved for adult GH deficiency. It bypasses endogenous feedback entirely and produces supraphysiological IGF-1 if overdosed. The Endocrine Society guidelines recommend rhGH for confirmed GHD; secretagogue stacks like sermorelin/ipamorelin are positioned as lower-risk options for patients with partial deficiency or age-related GH decline who do not meet strict GHD criteria [7].

Practical Injection Technique

Correct subcutaneous injection technique affects both efficacy and tolerability. Here is the standard approach used by HealthRX-supervised patients.

1. Wash hands with soap and water for at least 20 seconds.
2. Wipe the rubber stopper of each vial with a fresh 70% isopropyl alcohol swab.
3. Draw the sermorelin dose first, then draw ipamorelin into the same 1 mL insulin syringe (29-gauge or finer, 0.5-inch needle).
4. Pinch 1 to 2 cm of subcutaneous fat at the injection site (periumbilical or lateral thigh).
5. Insert the needle at a 45-degree angle; depress the plunger steadily over 5 seconds.
6. Apply gentle pressure with a dry swab. Do not rub.
7. Dispose of the needle in a sharps container immediately.

The combined volume of two peptides at 200 mcg each (from typical 2 mg/mL reconstitution) is 0.2 mL per peptide, or 0.4 mL total, which is comfortable in a standard 0.5 mL insulin syringe.

Evidence Gaps and Honest Limitations

The evidence base for this specific stack deserves a candid assessment. This article draws on:

• Sermorelin Phase 3 data reviewed in the FDA-approved label [5]
• Ipamorelin pharmacology from the 1998 Raun study in animal models [2]
• GHRH/GHRP co-administration from Bowers et al. In animal models [3]
• GHRH analogue RCTs (tesamorelin, not sermorelin) in human subjects [9]
• Endocrine Society clinical guidelines for adult GH deficiency [7]

What does not exist: a double-blind, placebo-controlled RCT of sermorelin plus ipamorelin in adult humans measuring body composition, IGF-1, or clinical outcomes. The absence of such a trial means this protocol rests on mechanistic inference and clinical experience, not Level 1 evidence. Patients should understand this before committing to a course.

The Endocrine Society's guideline language is direct on this point: "We recommend against the use of GH secretagogues for anti-aging purposes outside of clinical trials because of the lack of evidence for long-term benefit and safety" [7]. Therapeutic use in patients with confirmed or suspected GH secretory insufficiency is a different clinical question, but the evidence gap applies broadly.